Search

Your search keyword '"MESH : Atherosclerosis"' showing total 6 results
Start Over Descriptor "MESH : Atherosclerosis" Topic mesh: humans
6 results on '"MESH : Atherosclerosis"'

1. Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry)

Author

Etienne Puymirat, Nicolas Danchin, Yves Cottin, Nadia Aissaoui, Tabassome Simon, Jean Ferrières, Gilles Lemesle, Francois Schiele, Pierre Coste, Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Lille 2 - Faculté de Médecine, Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service de Cardiologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital cardiologique du Haut Leveque, Université de Bordeaux Ségalen [Bordeaux 2], Département de Cardiologie (Dep Cardio - BESANCON), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie [Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], CHU Saint-Antoine [APHP], Université Pierre et Marie Curie - Paris 6 (UPMC), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service de cardiologie [CHRU de Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Descartes - Paris 5 ( UPD5 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Lipides - Nutrition - Cancer [Dijon - U1231] ( LNC ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Département de Cardiologie ( Dep Cardio - BESANCON ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Épidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps, Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Plateforme de recherche clinique de l'est parisien ( URCEST-CRCEST ), Service de pharmacologie clinique [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Université Pierre et Marie Curie - Paris 6 ( UPMC ), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps [Toulouse], Université Paul Sabatier - Toulouse 3 ( UPS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paul Sabatier - Toulouse 3 ( UPS ) -CHU Toulouse [Toulouse]-Hôpital de Rangueil, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Faculté de Médecine Henri Warembourg - Université de Lille, Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Cardiologie [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
Male, MESH : Atherosclerosis, medicine.medical_treatment, MESH : Mortality, Myocardial Infarction, MESH : Aged, MESH : Prospective Studies, Angiotensin-Converting Enzyme Inhibitors, Coronary Artery Disease, Disease, MESH : Cerebrovascular Disorders, 0302 clinical medicine, Medicine, Longitudinal Studies, Prospective Studies, MESH: Coronary Artery Disease, Myocardial infarction, Coronary Artery Bypass, MESH: Treatment Outcome, Cause of death, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH : Platelet Aggregation Inhibitors, Prognosis, MESH: Case-Control Studies, 3. Good health, MESH: Myocardial Infarction, MESH: Angiotensin Receptor Antagonists, MESH : Angiotensin-Converting Enzyme Inhibitors, Cardiology and Cardiovascular Medicine, MESH: Percutaneous Coronary Intervention, MESH : Case-Control Studies, medicine.medical_specialty, MESH : Angiotensin Receptor Antagonists, MESH: Prognosis, 03 medical and health sciences, Percutaneous Coronary Intervention, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Humans, MESH : Middle Aged, MESH : Coronary Artery Disease, MESH : Aged, 80 and over, MESH: Hydroxymethylglutaryl-CoA Reductase Inhibitors, education, MESH: Age Distribution, Aged, MESH: Humans, MESH: Mortality, Proportional hazards model, MESH: Coronary Artery Bypass, MESH : Humans, Case-control study, MESH : Proportional Hazards Models, medicine.disease, MESH : Coronary Artery Bypass, Case-Control Studies, MESH: Female, MESH: Registries, MESH : Age Distribution, 030204 cardiovascular system & hematology, MESH: Atherosclerosis, MESH: Proportional Hazards Models, MESH: Cause of Death, MESH: Aged, 80 and over, MESH : Percutaneous Coronary Intervention, Risk Factors, MESH: Risk Factors, Cause of Death, MESH : Female, Registries, 030212 general & internal medicine, MESH: Longitudinal Studies, MESH : Longitudinal Studies, MESH: Aged, MESH : Prognosis, MESH: Angiotensin-Converting Enzyme Inhibitors, MESH: Adrenergic beta-Antagonists, Middle Aged, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, MESH : Risk Factors, Treatment Outcome, MESH: Platelet Aggregation Inhibitors, Cardiology, Female, MESH: Cerebrovascular Disorders, France, MESH : Male, Adrenergic beta-Antagonists, MESH : Adrenergic beta-Antagonists, Population, MESH : Treatment Outcome, MESH: Multivariate Analysis, Angiotensin Receptor Antagonists, Age Distribution, Internal medicine, Mortality, MESH : France, Proportional Hazards Models, MESH : Cause of Death, business.industry, MESH : Hydroxymethylglutaryl-CoA Reductase Inhibitors, MESH : Multivariate Analysis, Percutaneous coronary intervention, Atherosclerosis, MESH: Male, MESH: Prospective Studies, MESH: France, Cerebrovascular Disorders, Multivariate Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, MESH : Myocardial Infarction, business, Platelet Aggregation Inhibitors, MESH : Registries
Abstract

IF 3.398; International audience; The prognosis of patients with acute myocardial infarction (AMI) has notably improved in the past 20 years. Using the French Registry of ST-Elevation and Non-ST-elevation Myocardial Infarction (FAST-MI) 2010 registry, we investigated whether previous manifestations of atherosclerotic disease (i.e., previous MI, or a history of any form of atherosclerotic disease) are at truly increased risk compared with those in whom AMI is the first manifestation of the disease. FAST-MI 2010 is a nationwide French registry including 3,079 patients with AMI, among whom 1,062 patients had a history of cardiovascular atherosclerotic disease and 498 patients had a history of MI. Overall, patients with a history of atherosclerotic disease (or MI) were older compared with patients without known cardiovascular disease (71 ± 13 vs 63 ± 14 years) and had higher cardiovascular risk profiles and co-morbidities. Using fully adjusted Cox multivariate analysis, previous manifestations of atherosclerotic disease were associated with higher 3-year mortality (hazard ratio 1.80, 95% confidence interval 1.40 to 2.31; p

Published
2017
Full Text
View/download PDF

2. Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?

Author

Morgane Baron, Anne Tailleux, Bart Staels, Chantal M. Boulanger, Récepteurs nucléaires, maladies cardiovasculaires et diabète ( EGID ), Université de Lille, Droit et Santé-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut Pasteur de Lille, Réseau International des Instituts Pasteur ( RIIP ) -Réseau International des Instituts Pasteur ( RIIP ) -Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Derudas, Marie-Hélène

Subjects
MESH : Stroke, MESH : Atherosclerosis, Peroxisome Proliferator-Activated Receptors, Myocardial Infarction, MESH: Peroxisome Proliferator-Activated Receptors, MESH : Cell-Derived Microparticles, MESH: Flow Cytometry, Disease, 030204 cardiovascular system & hematology, Bioinformatics, Cardiovascular System, Antioxidants, MESH: Atherosclerosis, 0302 clinical medicine, Cell-Derived Microparticles, Risk Factors, MESH: Risk Factors, MESH: Cell-Derived Microparticles, Medicine, MESH: Animals, Pharmacological modulation, Myocardial infarction, MESH: Hypolipidemic Agents, Prospective cohort study, Stroke, Hypolipidemic Agents, microparticles, 0303 health sciences, MESH : Hypolipidemic Agents, MESH: Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Thrombosis, MESH : Risk Factors, MESH : Enzyme-Linked Immunosorbent Assay, Pathophysiology, 3. Good health, MESH : Thrombosis, MESH: Myocardial Infarction, Molecular Medicine, MESH : Antioxidants, MESH : Flow Cytometry, Reviews, Enzyme-Linked Immunosorbent Assay, MESH: Stroke, 03 medical and health sciences, MESH : Cardiovascular System, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Animals, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH: Thrombosis, [ SDV.BBM ] Life Sciences [q-bio]/Biochemistry, Molecular Biology, 030304 developmental biology, MESH: Humans, business.industry, MESH: Cardiovascular System, MESH: Antioxidants, MESH : Humans, MESH: Biological Markers, biomarkers, Cell Biology, Atherosclerosis, medicine.disease, MESH : Disease Models, Animal, MESH : Peroxisome Proliferator-Activated Receptors, cardiovascular diseases, MESH : Biological Markers, Disease Models, Animal, Immunology, MESH : Animals, MESH: Disease Models, Animal, MESH : Myocardial Infarction, business
Abstract

International audience; Cardiovascular diseases remain an important cause of morbi-mortality. Atherosclerosis, which predisposes to cardiovascular disorders such as myocardial infarction and stroke, develops silently over several decades. Identification of circulating biomarkers to evaluate cardiovascular event risk and pathology prognosis is of particular importance. Microparticles (MPs) are small vesicles released from cells upon apoptosis or activation. Microparticles are present in blood of healthy individuals. Studies showing a modification of their concentrations in patients with cardiovascular risk factors and after cardiovascular events identify MPs as potential biomarkers of disease. Moreover, the pathophysiological properties of MPs may contribute to atherosclerosis development. In addition, pharmacological compounds, used in the treatment of cardiovascular disease, can reduce plasma MP concentrations. Nevertheless, numerous issues remain to be solved before MP measurement can be applied as routine biological tests to improve cardiovascular risk prediction. In particular, prospective studies to identify the predictive values of MPs in pathologies such as cardiovascular diseases are needed to demonstrate whether MPs are useful biomarkers for the early detection of the disease and its progression.

Published
2012
Full Text
View/download PDF

3. PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH

Author

Aurélie S. Leroyer, Anne Tailleux, Philippe Delerive, Emmanuelle Vallez, Morgane Baron, Fanny Lalloyer, Kadiombo Bantubungi, Chantal M. Boulanger, Bart Staels, Zouher Majd, Giulia Chinetti-Gbaguidi, Derudas, Marie-Hélène, Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Genfit, Entreprise biopharmaceutique GENFIT Loos, This work was supported by grants of EU grant Hepadip 018734, the Foundation Coeur et Artères and Région Nord-Pas de Calais / FEDER, Récepteurs nucléaires, maladies cardiovasculaires et diabète ( EGID ), Réseau International des Instituts Pasteur ( RIIP ) -Réseau International des Instituts Pasteur ( RIIP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)

Subjects
Pathology, MESH : Fatty Liver, MESH : Atherosclerosis, MESH : Cell-Derived Microparticles, MESH: Flow Cytometry, 030204 cardiovascular system & hematology, MESH: Mice, Knockout, murine model, MESH: Atherosclerosis, Mice, 0302 clinical medicine, Fenofibrate, Cell-Derived Microparticles, Non-alcoholic Fatty Liver Disease, MESH: Cell-Derived Microparticles, MESH : Female, MESH: Animals, MESH: PPAR alpha, MESH: Fatty Liver, Mice, Knockout, microparticles, 0303 health sciences, medicine.diagnostic_test, Fatty liver, Flow Cytometry, MESH : Mice, Transgenic, Liver, Female, medicine.symptom, Cardiology and Cardiovascular Medicine, medicine.drug, medicine.medical_specialty, MESH : Flow Cytometry, MESH: Mice, Transgenic, Transgene, MESH : PPAR alpha, Inflammation, Mice, Transgenic, MESH : Mice, Inbred C57BL, Biology, Flow cytometry, 03 medical and health sciences, MESH: Mice, Inbred C57BL, Internal medicine, MESH : Mice, medicine, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Animals, Humans, PPAR alpha, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, [ SDV.BBM ] Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH: Mice, 030304 developmental biology, MESH: Humans, MESH : Humans, MESH: Biological Markers, MESH : Liver, nutritional and metabolic diseases, medicine.disease, MESH: Fenofibrate, MESH : Disease Models, Animal, Fatty Liver, Mice, Inbred C57BL, MESH : Biological Markers, Disease Models, Animal, Endocrinology, Nuclear receptor, Apoptosis, MESH : Mice, Knockout, fatty liver disease, MESH : Animals, Steatohepatitis, atherosclerosis, pharmacology, MESH: Disease Models, Animal, MESH : Fenofibrate, MESH: Female, Biomarkers, MESH: Liver
Abstract

International audience; BACKGROUND: Atherosclerosis and non-alcoholic fatty liver disease (NAFLD) are complex pathologies characterized by lipid accumulation, chronic inflammation and extensive tissue remodelling. Microparticles (MPs), small membrane vesicles produced by activated and apoptotic cells, might not only be biomarkers, but also functional actors in these pathologies. The apoE2-KI mouse is a model of atherosclerosis and NAFLD. Activation of the nuclear receptor PPARα decreases atherosclerosis and components of non-alcoholic steatohepatitis (NASH) in the apoE2-KI mouse. OBJECTIVES: (1) To determine whether MPs are present in atherosclerotic lesions, liver and plasma during atherosclerosis and NASH progression in apoE2-KI mice, and (2) to study whether PPARα activation modulates MP concentrations. METHODS: ApoE2-KI mice were fed a Western diet to induce atherosclerosis and NASH. MPs were isolated from atherosclerotic lesions, liver and blood and quantified by flow cytometry. RESULTS: An increase of MPs was observed in the atherosclerotic lesions and in the liver of apoE2-KI mice upon Western diet feeding. PPARα activation with fenofibrate decreased MP levels in the atherosclerotic lesions in a PPARα-dependent manner, but did not influence MP concentrations in the liver. CONCLUSION: Here we report that MPs are present in atherosclerotic lesions and in the liver of apoE2-KI mice. Their concentration increased during atherosclerosis and NASH development. PPARα activation differentially modulates MP levels in a tissue-specific manner.

Published
2011
Full Text
View/download PDF

4. Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers

Author

Mallat, Ziad, Lambeau, Gérard, Tedgui, Alain, Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut de pharmacologie moléculaire et cellulaire ( IPMC ), Université Nice Sophia Antipolis ( UNS ), and Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
MESH: Inflammation, MESH: Group IV Phospholipases A2, MESH : Atherosclerosis, MESH : Polymorphism, Genetic, Lipoproteins, enzymes, MESH : Group VI Phospholipases A2, MESH : Lipoproteins, MESH: Prognosis, MESH: Atherosclerosis, Group VI Phospholipases A2, MESH : Group IV Phospholipases A2, Predictive Value of Tests, MESH: Polymorphism, Genetic, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH: Group VI Phospholipases A2, Humans, MESH : Predictive Value of Tests, ComputingMilieux_MISCELLANEOUS, Inflammation, MESH : Inflammation, MESH : Prognosis, MESH: Humans, Polymorphism, Genetic, Group IV Phospholipases A2, MESH : Humans, MESH: Biological Markers, MESH: Lipoproteins, Atherosclerosis, Prognosis, MESH: Predictive Value of Tests, MESH : Biological Markers, [SDV.IMM]Life Sciences [q-bio]/Immunology, Biomarkers
Abstract

International audience

Published
2010
Full Text
View/download PDF

5. G-765C COX-2 gene promoter polymorphism and risk of atherosclerosis after kidney transplantation

Author

Jamal Bamoulid, Christophe Legendre, Cécile Courivaud, Jean-Marc Chalopin, Philippe Saas, Eric Thervet, Pierre Tiberghien, Didier Ducloux, Saas, Philippe, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'urologie, andrologie et transplantation rénale, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Plateforme de Biomonitoring, Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Service de néphrologie adultes [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ), and Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP]

Subjects
Male, MESH : Atherosclerosis, MESH : Promoter Regions, Genetic, 030204 cardiovascular system & hematology, MESH: Atherosclerosis, MESH: Kidney Transplantation, Cohort Studies, 0302 clinical medicine, Gene Frequency, Risk Factors, MESH: Risk Factors, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH : Female, MESH : Gene Frequency, Promoter Regions, Genetic, MESH: Cohort Studies, Kidney transplantation, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, MESH: Middle Aged, MESH: Polymorphism, Single Nucleotide, MESH : Polymorphism, Single Nucleotide, MESH : Adult, Middle Aged, MESH : Risk Factors, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, MESH: Cyclooxygenase 2, Adult, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH : Cyclooxygenase 2, MESH : Male, MESH : Cohort Studies, Polymorphism, Single Nucleotide, 03 medical and health sciences, MESH: Promoter Regions, Genetic, medicine, MESH: Gene Frequency, Humans, MESH : Middle Aged, 030304 developmental biology, Transplantation, MESH: Humans, business.industry, MESH : Humans, Promoter, MESH: Adult, Atherosclerosis, medicine.disease, Kidney Transplantation, MESH: Male, Cyclooxygenase 2, Cancer research, MESH : Kidney Transplantation, business, MESH: Female
Abstract

International audience

Published
2009
Full Text
View/download PDF

6. Swallowing, arterial pulsation, and breathing induce motion artifacts in carotid artery MRI

Author

Loic Boussel, Philippe Douek, Jean Michel Serfaty, Gwenael Herigault, Michel Nonent, Alejandro de la Vega, Laboratoire Creatis, Compte Général, Hôpital Cardiovasculaire Louis Pradel ( HCLP ), Hospices Civils de Lyon ( HCL ), Philips Medical Systems ( PMS ), Philips Medical Systems, Département de radiologie [Brest] ( DR - Brest ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), Département de Radiologie, Université Xavier Bichat, Hôpital Cardiovasculaire Louis Pradel (HCLP), Hospices Civils de Lyon (HCL), Philips Medical Systems (PMS), Département de radiologie [Brest] (DR - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Centre de Recherche et d'Application en Traitement de l'Image et du Signal (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-École Supérieure Chimie Physique Électronique de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Carotid Artery Diseases, Male, MESH : Motion, MESH : Atherosclerosis, MESH : Deglutition, Pulsatile flow, MESH : Aged, MESH : Carotid Arteries, [INFO.INFO-IM] Computer Science [cs]/Medical Imaging, Magnetic resonance angiography, MESH : Artifacts, 030218 nuclear medicine & medical imaging, MESH: Magnetic Resonance Imaging, MESH: Atherosclerosis, 0302 clinical medicine, [INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing, Image Processing, Computer-Assisted, MESH : Female, MESH: Aged, MESH: Middle Aged, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, medicine.diagnostic_test, Respiration, Isocenter, Middle Aged, MESH : Adult, Magnetic Resonance Imaging, MESH: Image Processing, Computer-Assisted, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Amplitude, Carotid Arteries, MESH: Artifacts, [INFO.INFO-TI] Computer Science [cs]/Image Processing [eess.IV], Pulsatile Flow, [INFO.INFO-TI]Computer Science [cs]/Image Processing [eess.IV], MESH: Pulsatile Flow, Cardiology, Breathing, Female, [INFO.INFO-MO] Computer Science [cs]/Modeling and Simulation, Artifacts, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, MESH : Image Processing, Computer-Assisted, Adult, medicine.medical_specialty, [INFO.INFO-TS] Computer Science [cs]/Signal and Image Processing, MESH: Motion, MESH : Male, Diastole, Lumen (anatomy), MESH : Pulsatile Flow, 03 medical and health sciences, Motion, Swallowing, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, MESH : Magnetic Resonance Imaging, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, medicine, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Humans, Radiology, Nuclear Medicine and imaging, MESH : Middle Aged, MESH : Carotid Artery Diseases, Aged, [SPI.SIGNAL] Engineering Sciences [physics]/Signal and Image processing, MESH: Respiration, MESH: Carotid Arteries, MESH: Humans, business.industry, MESH: Carotid Artery Diseases, MESH : Humans, MESH: Adult, Atherosclerosis, [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation, MESH: Male, Deglutition, MESH : Respiration, MESH: Deglutition, business, MESH: Female, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Purpose To identify and quantify the potential sources of motion in carotid artery imaging. Materials and Methods Two healthy volunteers and 12 patients (20–75 years old) with atherosclerotic disease were scanned on a Philips Intera 1.5T system. A single-shot balanced-fast field echo (bFFE) sequence was used to acquire real-time axial views of the carotid artery wall (three images per second). A three-step acquisition protocol was performed to analyze the three types of motion (arterial pulsation, breathing, and swallowing) separately. The isocenter carotid artery motion amplitude in either the x or y direction was measured. Radial variation in the carotid lumen between the systolic and diastolic phases was analyzed. Motion frequency was reported for each patient. Results Significant motion related to arterial pulsation (amplitude = 0.27–0.93 mm, mean = 0.6, SD = 0.19), breathing (amplitude = 0.5–3.6 mm, mean = 1.56, SD = 0.99)), and swallowing (amplitude = 1.4–9.2 mm, mean = 4.7, SD = 2.4) were visualized. Conclusion Pulsation, breathing, and swallowing are sources of significant motion in the carotid artery wall. Such motion should be considered in the future to improve carotid artery image quality. J. Magn. Reson. Imaging 2006. © 2006 Wiley-Liss, Inc.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results